semaglutide heart failure trial Analysis of the SELECT showed that #semaglutide reduced the risks of major adverse cardiovascular events and failure, irrespective of A1c. https://t.co/uCb2P5E8mB STEP-HFpEF DM Trial Hints at

GLP-1-RA such as liraglutide [4], semaglutide [5], and the dual agonist tirzepatide [6], activating both the GLP1- and the gastric-inhibitory polypeptide receptor (GIP-R), have been shown to significantly reduce body weight, making them a promising therapeutic option for the treatment of obesity

Other challenges There are several other challenges inherent to GLP-1 drugs, including: Cost and accessibility: The high cost of many GLP-1 agonists remains a significant barrier for many patients, with some insurance plans not covering these medications, particularly for obesity management

Finally, Glp1r / and their wild-type mice were administered GLP-1 (3 nmol/50 l, i.p.) or saline at 10:00, subsequently given a ghrelin (1.5 nmol/50 l, i.p.) or saline injection at 10:30, food intake was measured from 10:30 to 11:30

The additional glucagon receptor activation is hypothesised to further increase energy expenditure

As you may be able to tell, losing weight with hypothyroidism is complex

They are suitable for occasional use when more rapid relief is needed but are not typically recommended as sole maintenance therapy